Ann Lab Med 2018; 38(6): 538-544  https://doi.org/10.3343/alm.2018.38.6.538
Serum Copeptin Levels Predict Clinical Outcomes After Successful Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
Hyun-Jung Choi, M.D.1*, Min Chul Kim, M.D.2*, Doo Sun Sim, M.D.2, Young Joon Hong, M.D.2, Ju Han Kim, M.D.2, Myung Ho Jeong, M.D.2, Soo-Hyun Kim, M.D.1, Myung-Geun Shin, M.D.1, and Youngkeun Ahn, M.D.2
1Departments of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, Hwasun, Korea; 2Department of Cardiology, Cardiovascular Center, Chonnam National University Hospital, Gwangju, Korea
Corresponding author: Myung-Geun Shin
https://orcid.org/0000-0002-0372-9185
Departments of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun 58128, Korea
Tel: +82-61-379-7950
Fax: +82-61-379-7984
E-mail: mgshin@chonnam.ac.kr
Co-corresponding author: Youngkeun Ahn
https://orcid.org/0000-0003-2022-9366
Department of Cardiology, Cardiovascular Center, Chonnam National University Hospital, 671 Jebong-ro, Dong-gu, Gwangju 61469, Korea
Tel: +82-62-220-4764
Fax: +82-62-224-4764
E-mail: cecilyk@hanmail.net
*These authors contributed equally to this work.
Received: October 25, 2017; Revised: January 16, 2018; Accepted: May 21, 2018; Published online: November 1, 2018.
© Korean Society for Laboratory Medicine. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: Serum copeptin has been demonstrated to be useful in early risk stratification and prognostication of patients with acute myocardial infarction (AMI). However, the prognostic value of copeptin after percutaneous coronary intervention (PCI) for clinical outcomes remains uncertain. We investigated the prognostic role of serum copeptin levels immediately after successful PCI as a prognostic marker for major adverse cardiac events (MACE; comprising death, repeat PCI, recurrent MI, or coronary artery bypass grafting) in patients with AMI.
Methods: A retrospective study was performed in 149 patients with AMI who successfully received PCI. Serum copeptin levels were analyzed in blood samples collected immediately after PCI. The association between copeptin levels and MACE during the follow-up period was evaluated.
Results: MACE occurred in 34 (22.8%) patients during a median follow-up of 30.1 months. MACE patients had higher copeptin levels than non-MACE patients did. Multiple logistic regression analysis showed that the increase in serum copeptin levels was associated with increased MACE incidence (odds ratio=1.6, P=0.005).
Conclusions: A high level of serum copeptin measured immediately after PCI was associated with MACE in patients with AMI during long-term follow-up. Serum copeptin levels can serve as a prognostic marker in patients with AMI after successful PCI.
Keywords: Copeptin, Prognosis, Major adverse cardiac events, Myocardial infarction, Percutaneous coronary intervention



This Article

e-submission

Archives

Indexed/Covered by